Mylan Sues FDA For Delaying Duragesic Generic
The largest U.S. generic drug maker also suspended its earnings forecast on Wednesday as its shares fell on the news that the company would not be able to sell the skin patch as early as previously indicated.
On Tuesday, the FDA granted Johnson & Johnson, which makes Duragesic, an additional six months of marketing exclusivity for the treatment. That...
To view the full article, register now.